A West Chester pharmaceutical company finally achieved federal approval of a new drug candidate that treats a contagious skin disease, writes John George for the Philadelphia Business Journal.

The fourth time Verrica Pharmaceutical applied for the approval of Ycanth proved to be successful.  

The application for Ycanth was resubmitted in January after the FDA rejected them three previous times. CEO Ted White called this “a historic transformational moment in medical dermatology.”  

Ycanth is a combination product that treats adults and children and is topically administered. Around 6 million people in the United States suffer from molloscum contagium. According to Verrica, the potential for the molluscum treatment could draw in more than $1 billion in the U.S. market.  

Ycanth is expected to be introduced in September of this year. In addition, the 22-employee company is also conducting mid-stage clinical testing of Ycanth to treat common warts.  

“Our commercial team is vigorously preparing for commercial launch, and we look forward to working with healthcare providers to give patients and caregivers access to Ycanth,” said White. 

Read more about the West Chester-based pharmaceutical company in the Philadelphia Business Journal.  

Why you should move to West Chester.